Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Https://twitter.com/search?q=%23cmrs&src=recent_search_click&f=live
relevant info
With this latest salvo, the shareholder base will not increase and existing holders are wondering what next. Which is what the BOD [now] want - they don't need PIs for funds therefore being listed is of no benefit. See where this is going? And any ultimate buyer would prefer to deal with a private company.
Volume today speaks volumes. Without any form of oversight, I fear this good company has become uninvestable.
I had thought wily old TB had missed a trick by having no warrants at say 2p. But he's done better - set a 1p figure in peep's minds, given himself free what he would have got if he participated in the placing - ]that went to safe hands] and the only other peeps that matter - the BOD, have now been bought and are now part of the plan.
300k is not enough to prevent another raise - £1m at 1p and he has control as and when he needs it.
I'll ask again - how long is 350k going to last. No guidance given of course, why on earth would you inform PIs of something so important? Bet you CLs will rear their ugly head again - as there is no financial info to assess / analyse, we are totally in the dark and the fiefdom continues to be ruled by our absolute monarch. I hope the FAB family remember the peeps who bought at 5p last month on the good RNS & based upon majority shareholder support assurance.
P -house. Well if all they can manage is 300k at 1.5p with no adverse news, hardly a ringing endorsement. Reality, they do as they are told, again hardly a ringing endorsement!
Asked before, how long will gross 370k last??
Funding will raise its ugly head again and then we are back to CLs etc etc.
Buy a few and leave them is my advice.
Yes, I think everyone did not realise how long and protracted the road to commerciality would be [not helped by FDA rebuff]
The product is not well suited to be developed by a small listed co with limited pockets in this market. It should have been [and may still well be] done in house of a multinational under a seperate cost centre. If this had been the case it may have been available already given the financial power and industry influence of a major.
Managment have a big stress on their hands which detracts / splits their time from getting on with the launch - and many of its holders can't / won't wait so long. Existing support is very lacklustre imo - they could turbo charge the company of they wanted to but they are dancing on the edges.
Sad but it needs to be absorbed asap to actually meet the medical needs it fulfills.